<code id='39569C2345'></code><style id='39569C2345'></style>
    • <acronym id='39569C2345'></acronym>
      <center id='39569C2345'><center id='39569C2345'><tfoot id='39569C2345'></tfoot></center><abbr id='39569C2345'><dir id='39569C2345'><tfoot id='39569C2345'></tfoot><noframes id='39569C2345'>

    • <optgroup id='39569C2345'><strike id='39569C2345'><sup id='39569C2345'></sup></strike><code id='39569C2345'></code></optgroup>
        1. <b id='39569C2345'><label id='39569C2345'><select id='39569C2345'><dt id='39569C2345'><span id='39569C2345'></span></dt></select></label></b><u id='39569C2345'></u>
          <i id='39569C2345'><strike id='39569C2345'><tt id='39569C2345'><pre id='39569C2345'></pre></tt></strike></i>

          Home / explore / focus

          focus


          focus

          author:comprehensive    Page View:13659
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In